18th Jan 2016 08:06
LONDON (Alliance News) - Life sciences company Abzena PLC on Monday said a consortium which includes its Antitope Ltd subsidiary has secured a EUR1.9 million European grant.
The consortium is developing a treatment for clotting disorders. The other companies involved in the consortium include Prothix BV and Aristi Biotech NV, two Dutch biopharmaceutical companies, the University Medical Center Utrecht in the Netherlands and France's GenOway.
"Applying our composite human antibody technology to this novel product will help produce a less immunogenic version, giving it a greater chance of improving the lives of patients," said Neil Butt, the vice-president of business development at Abzena.
Shares in Abzena were untraded early Monday, having last traded at 54.00 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Abzena